# Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction

> **NCT02033590** · NA · WITHDRAWN · sponsor: **Sofregen Medical, Inc.**

## Conditions studied

- Breast Reconstruction

## Interventions

- **DEVICE:** Biodegradable (purified) surgical silk scaffold

## Key facts

- **NCT ID:** NCT02033590
- **Lead sponsor:** Sofregen Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic priorities impacted study
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02033590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02033590, "Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02033590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*